Malin (MLC.IR)

Executive Summary

Malin is a Dublin-based life sciences investment company that builds and supports healthcare businesses focused on biologics, oncology, and rare diseases. Founded in 2014, it operates as a strategic investor, providing capital and operational expertise to develop and commercialize innovative medical technologies. The company's portfolio includes early-stage to commercial-stage companies, with a focus on high-value therapeutic areas. Malin's model combines financial investment with hands-on strategic guidance to advance promising assets toward regulatory and commercial milestones. The company is publicly traded on the Irish Stock Exchange under ticker MLC.IR, with a current valuation of approximately $34 million. Despite limited recent public disclosures, Malin continues to manage its portfolio and seek new opportunities in the life sciences sector.

Upcoming Catalysts (preview)

• Q4 2026Portfolio Company Milestone Announcements60% success
• Q2 2026New Investment or Partnership Deal50% success
• Q3 2026Potential Exit or Monetization of Stake40% success